Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
Topline readout of data from NORSE TWO targeted for calendar Q3 2021New Biologics License Application (BLA) filing anticipated in calendar...
Topline readout of data from NORSE TWO targeted for calendar Q3 2021New Biologics License Application (BLA) filing anticipated in calendar...
Los Angeles , June 08, 2021 (GLOBE NEWSWIRE) -- OOTify, a new mental health hub powered by artificial intelligence (AI),...
Study demonstrates Scipher Medicine’s ability to analyze patient data to identify novel treatments.Scipher will focus on pharma collaborations in autoimmune...
SAINT LAURENT, Quebec, June 08, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today...
SEATTLE, June 08, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived tumor...
Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwideNASHUA, N.H., June...
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE)...
PRESS RELEASE June 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it...
– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory...
SYDNEY, AUSTRALIA, June 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading...
CRESSKILL, N.J. and JERUSALEM, June 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Dr. Pepose is Recognized as an Esteemed Key Opinion Leader in Ophthalmology with Nearly 40 Years of Experience as a...
Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients...
Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumabJENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V....
DENVER, June 08, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’),...
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a Canadian public biotechnology company...
Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in...
- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications - - Continued development in COVID-19-related...
BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on...
Approval of aducanumab offers real hope for patients and fuels development of next-generation therapies with more selective binding for toxic...